The court has reached a verdict in a patent infringement suit brought against a worldwide developer, manufacturer and marketer of medical devices, the Boston Scientific Corporation (NYSE: BSX).
The suit was filed by Dr. Bruce Saffran, who claimed that the company's TAXUS(R) Express(R) and TAXUS(R) Liberte(TM) drug-eluting stent products violated Dr. Saffran's patent while the latter being valid.
The jury awarded Dr. Saffran damages of $431 million.
The company manufactures products used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Boston Scientific is well known for the development of the Taxus Stent, a drug-coated stent which is used to open clogged arteries.
Boston Scientific plans to overturn the verdict on the basis of suppositions that the verdict is unsupported by both the evidence and the law.
The behavior of the Russian inspector satellite, which was launched in the autumn of 2017, puzzles military officials in the United States
When the bill was submitted to Congress on August 2, the reason for imposing the new sanctions on Russia was based on Russia's alleged interference in the US presidential election in 2016, but then something clicked
Vladimir Putin is planning to attend the wedding ceremony of Austria's Foreign Minister Karin Kneissl on the way to Berlin